JHEP Reports

Our new Impact Factor is 9.5!! Many thanks to the Editorial Team, our peer reviewers, and very innovative authors! EASL | The Home of Hepatology

As we're gearing up for the weekend, why not take a moment to plan something exciting for June? Join us at #EASLCongress from 5-8 June in Milan, or participate online from anywhere in the world. 💡Explore cutting-edge research, engage with experts, and expand your knowledge in hepatology and liver health. Don't miss this opportunity to be part of one of the biggest events in the field! 👉https://lnkd.in/ei7dcixf

Happy #WorldLiverDay! EASL Secretary General, Prof. Aleksander Krag’s highlights the urgent need for action in liver health on #WorldLiverDay. Most cases of liver disease are preventable. Early detection, lifestyle changes and public health measures are vital. Watch the video and join the campaign! worldliverday.org World Liver Day

Transplant oncology – Current indications and strategies to advance the field Liver transplantation (LT) was originally described by Starzl as a promising strategy to treat primary malignancies of the liver. Confronted with high recurrence rates, indications drifted towards non-oncologic liver diseases with LT finally evolving from a high-risk surgery to an almost routine surgical procedure. Continuously improving outcomes following LT and evolving oncological treatment strategies have driven renewed interest in transplant oncology. This is not only reflected by constant refinements to the criteria for LT in patients with HCC, but especially by efforts to expand indications to other primary and secondary liver malignancies. With new patient-centred oncological treatments on the rise and new technologies to expand the donor pool, the field has the chance to come full circle. In this review, we focus on the concept of transplant oncology, current indications, as well as technical and ethical aspects in the context of donor organs as precious resources. Review by Felix Julius Krendl, Manuel Maglione et al. #OpenAccess here: https://lnkd.in/dRbnbR4w EASL | The Home of Hepatology

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with an increased risk of multisystemic complications, including muscle changes such as sarcopenia and myosteatosis that can reciprocally affect liver function. We conducted a systematic review to highlight innovative assessment tools, pathophysiological mechanisms and metabolic consequences related to myosteatosis in MASLD, based on original articles screened from PUBMED, EMBASE and COCHRANE databases. Forty-six original manuscripts (14 pre-clinical and 32 clinical studies) were included. Microscopy (8/14) and tissue lipid extraction (8/14) are the two main assessment techniques used to measure muscle lipid content in pre-clinical studies. In clinical studies, imaging is the most used assessment tool and included CT (14/32), MRI (12/32) and ultrasound (4/32). Assessed muscles varied across studies but mainly included paravertebral (4/14 in pre-clinical; 13/32 in clinical studies) and lower limb muscles (10/14 in preclinical; 13/32 in clinical studies). Myosteatosis is already highly prevalent in non-cirrhotic stages of MASLD and correlates with disease activity when using muscle density assessed by CT. Numerous pathophysiological mechanisms were found and included: high-fat and high-fructose diet, dysregulation in fatty acid transport and ketogenesis, endocrine disorders and impaired microRNA122 pathway signalling. In this review we also uncover several potential consequences of myosteatosis in MASLD, such as insulin resistance, MASLD progression from steatosis to metabolic steatohepatitis and loss of muscle strength. In conclusion, data on myosteatosis in MASLD are already available. Screening for myosteatosis could be highly relevant in the context of MASLD, considering its correlation with MASLD activity as well as its related consequences. Review by Guillaume Henin, Audrey Loumaye, Isabelle A. Leclercq and Nicolas Lanthier #OpenAccess here: https://lnkd.in/dStHHCht EASL | The Home of Hepatology

Roles of innate lymphoid cells in metabolic and alcohol-associated liver diseases Innate lymphoid cells (ILCs) have been identified as potent regulators of inflammation, cell death and wound healing, which are the main biological processes involved in the progression of chronic liver disease. Obesity and chronic alcohol consumption are the leading contributors to chronic liver diseases in developed countries, due to inappropriate lifestyles. In particular, inflammation is a key factor in these liver abnormalities and promotes the development of more severe lesions such as fibrosis, cirrhosis and hepatocellular carcinoma. Opposite roles of ILC subsets have been described in the development of chronic liver disease, depending on the stage and aetiology of the disease. The heterogeneous family of ILCs encompasses cytotoxic natural killer cells, the cytokine-producing type 1, 2 and 3 ILCs and lymphoid tissue inducer cells. Dysfunction of these immune cells provokes uncontrolled inflammation and tissue damage, which are the basis for tumour development. In this review, we provide an overview of the recent and putative roles of ILC subsets in obesity and alcohol-associated liver diseases, which are currently the major contributors to end-stage liver complications such as fibrosis/cirrhosis and hepatocellular carcinoma. Review by Manon BOURINET, Rodolphe Anty, GUAL Philippe and Carmelo Luci #OpenAccess here: https://lnkd.in/dhXNiBJq EASL | The Home of Hepatology